.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,273,734

« Back to Dashboard

Claims for Patent: 8,273,734

Title:5HT.sub.2C receptor modulators
Abstract: The present invention relates to novel compounds of Formula (I): ##STR00001## which act as 5HT.sub.2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Inventor(s): Smith; Brian (San Diego, CA), Smith; Jeffrey (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/523,805
Patent Claims: 1. A method for weight loss in a subject comprising administering to said subject a pharmaceutically effective amount of a pharmaceutically acceptable salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, wherein said subject has at least one weight related condition chosen from sleep apnea, hypertension, cardiovascular disease, and diabetes.

2. The method of claim 1, wherein said subject has sleep apnea.

3. The method of claim 1, wherein said subject has hypertension.

4. The method of claim 1, wherein said subject has cardiovascular disease.

5. The method of claim 1, wherein said subject has diabetes.

6. The method of claim 1, wherein said subject has a BMI greater than 30 kg/m.sup.2.

7. The method of claim 1, wherein said subject has a BMI ranging from 25.0 to 29.9 kg/m.sup.2.

8. The method of claim 1, wherein the subject has greater than 25% body fat content if male and greater than 30% body fat content if female.

9. The method of claim 1, further comprising advising said subject to increase physical activity.

10. The method of claim 1, further comprising advising said subject to reduce dietary fat content.

11. The method of claim 1, further comprising advising said subject to consume fewer calories.

12. A method of controlling weight gain of a subject comprising administering to said subject a pharmaceutically effective amount of a pharmaceutically acceptable salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, wherein said subject has at least one weight related condition chosen from sleep apnea, hypertension, cardiovascular disease, and diabetes.

13. The method of claim 12, wherein said subject has sleep apnea.

14. The method of claim 12, wherein said subject has hypertension.

15. The method of claim 12, wherein said subject has cardiovascular disease.

16. The method of claim 12, wherein said subject has diabetes.

17. The method of claim 12, wherein said subject has a BMI greater than 30 kg/m.sup.2.

18. The method of claim 12, wherein said subject has a BMI ranging from 25.0 to 29.9 kg/m.sup.2.

19. The method of claim 12, wherein the subject has greater than 25% body fat content if male and greater than 30% body fat content if female.

20. The method of claim 12, further comprising advising said subject to increase physical activity.

21. The method of claim 12, further comprising advising said subject to reduce dietary fat content.

22. The method of claim 12, further comprising advising said subject to consume fewer calories.

23. A method for maintaining weight in a subject comprising administering to said subject a pharmaceutically effective amount of a pharmaceutically acceptable salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, wherein said subject has at least one weight related condition chosen from sleep apnea, hypertension, cardiovascular disease, and diabetes.

24. The method of claim 23, wherein said maintaining weight comprises maintaining weight after weight loss.

25. The method of claim 23, wherein said subject has sleep apnea.

26. The method of claim 23, wherein said subject has hypertension.

27. The method of claim 23, wherein said subject has cardiovascular disease.

28. The method of claim 23, wherein said subject has diabetes.

29. The method of claim 23, wherein said subject has a BMI greater than 30 kg/m.sup.2.

30. The method of claim 23, wherein said subject has a BMI ranging from 25.0 to 29.9 kg/m.sup.2.

31. The method of claim 23, wherein the subject has greater than 25% body fat content if male and greater than 30% body fat content if female.

32. The method of claim 23, further comprising advising said subject to increase physical activity.

33. The method of claim 23, further comprising advising said subject to reduce dietary fat content.

34. The method of claim 23, further comprising advising said subject to consume fewer calories.

35. A method for treatment of obesity of a subject comprising administering to said subject a pharmaceutically effective amount of a pharmaceutically acceptable salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, wherein said subject has at least one weight related condition chosen from sleep apnea, hypertension, cardiovascular disease, and diabetes.

36. The method of claim 35, wherein said subject has sleep apnea.

37. The method of claim 35, wherein said subject has hypertension.

38. The method of claim 35, wherein said subject has cardiovascular disease.

39. The method of claim 35, wherein said subject has diabetes.

40. The method of claim 35, wherein said subject has a BMI greater than 30 kg/m.sup.2.

41. The method of claim 35, wherein said subject has a BMI ranging from 25.0 to 29.9 kg/m.sup.2.

42. The method of claim 35, wherein the subject has greater than 25% body fat content if male and greater than 30% body fat content if female.

43. The method of claim 35, further comprising advising said subject to increase physical activity.

44. The method of claim 35, further comprising advising said subject to reduce dietary fat content.

45. The method of claim 35, further comprising advising said subject to consume fewer calories.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc